- Asia Pacific
- South Africa
- Hong Kong
- New Zealand
- Czech Republic
- United Kingdom
Recent Pfizer Press Releases
Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference9/19/07 12:46 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Martin Mackay, Vice President, Pfizer Global Research & Development, Senior Vice President Worldwide Development, at the UBS Life Sciences Conference on Wednesday, September 26 at 8:30am Eastern Daylight Savings Time. To view and listen to the webcast, visit our web site homepage at www.pfizer.com and click onmore...
Long-Term Data Reinforce Safety and Efficacy Profile of Pfizer's New HIV Drug Selzentry(TM) (Maraviroc)9/18/07 11:00 am EDT
Selzentry Now Available Throughout the U.S. for Use in Combination Therapy for Certain Treatment-Experienced HIV PatientsCHICAGO--(BUSINESS WIRE)--Nearly three times as many patients receiving Selzentry, in addition to an optimized background regimen, achieved undetectable levels of HIV virus compared with those receiving an optimized regimen alone, according to 48 week data presented today in late-breaking sessions at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting. This newly approved CCR5 antagonist – the first new class ofmore...
9/18/07 3:00 am EDT
A Second Exploratory Study Comparing Exubera and Lantus Assessed Daily Blood Sugar Levels in Patients with Type 2 DiabetesAMSTERDAM, Netherlands--(BUSINESS WIRE)--Two new studies presented today at the European Association for the Study of Diabetes (EASD) meeting reinforce the efficacy and safety of Exubera (insulin human [rDNA origin]) Inhalation Powder for adults with diabetes. An eight-year extension study showed that Exubera was well-tolerated and effective at maintaining blood sugar control. A second eight-day, exploratory study with Exubera and Lantus® (more...
Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference9/13/07 3:38 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Ian Read, Senior Vice President, Pfizer Inc., President, Worldwide Pharmaceutical Operations, at the 37th Annual Bank of America Investment Conference on Wednesday, September 19 at 9:00 a.m. Pacific Daylight Savings Time. To view and listen to the webcast, visit our web site homepage at www.pfizer.com and click onmore...
Pfizer to Share New Data and Portfolio Update on Infectious Disease Portfolio at ICAAC Meeting; Invites Public to View and Listen to Webcast of September 18 Analyst Meeting9/13/07 11:44 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the company plans to present key data on in-line medicines and pipeline research at the Annual Meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago, Illinois. In addition, Pfizer plans to host an investor meeting on September 18th to review key updates on infectious disease medicines and pipeline research. The meeting will be webcast live from Chicagomore...
9/12/07 5:02 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Canadian Federal Court in Toronto has ruled that Pfizer’s patent covering a crystalline form of atorvastatin, the active ingredient in Lipitor, would be infringed by Ranbaxy Laboratories Limited’s process for making their proposed generic atorvastatin product. The court granted the company’s application for an order preventing Ranbaxy from launching its product untilmore...
Pfizer Oncology Initiates Global Phase III Trial to Evaluate Sunitinib Malate Combined with Erlotinib in Advanced Non-Small Cell Lung Cancer9/5/07 11:30 pm EDT
Phase II Preliminary Data for Sunitinib Presented at the 12th World Conference on Lung CancerSEOUL, Korea--(BUSINESS WIRE)--Pfizer announced today the initiation of a large, global Phase III clinical trial to evaluate the efficacy and safety of sunitinib malate, in combination with erlotinib, in previously treated patients with advanced non-small cell lung cancer (NSCLC). In addition, preliminary results from a Phase II study, presented this week at the International Association for the Study of Lung Cancer (IASLC) World Conference in Seoul,more...
Pfizer Launches Five Year, Three Country Initiative for Malaria Treatment and Education - Mobilize Against Malaria9/5/07 11:28 am EDT
Pfizer Announces Key Partnerships with Leading International and Local Organizations to Benefit Patients in Kenya, Ghana and SenegalNAIROBI--(BUSINESS WIRE)--To help address critical gaps in malaria treatment and education, Pfizer today announced the launch of Mobilize Against Malaria. This three-country initiative comprising Kenya, Ghana and Senegal will be implemented over the course of five years (2007-2011). Pfizer has selected key international and local health experts to develop and implement public health interventions that engage and educate treatment providers and patientsmore...
Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference9/5/07 11:00 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Pfizer Inc. Chairman and Chief Executive Officer Jeffrey B. Kindler at the 20th Annual Bear Stearns Health Care Conference on Monday, September 10th at 1:30p.m. Eastern Daylight Savings Time. To view and listen to the webcast, visit our web site homepage at www.pfizer.com and click on the “the 20thmore...
Patients Who Switched from Established Lipitor Therapy to Simvastatin Experienced a Significant 30 Percent Increase in Relative Risk of Cardiovascular Events or Death, New Observational Study Shows9/5/07 2:03 am EDTVIENNA, Austria--(BUSINESS WIRE)--An observational study of a large United Kingdom primary care database showed that switching patients from Pfizer’s Lipitor® (atorvastatin calcium) Tablets to simvastatin was associated with a 30 percent increase in the relative risk of major cardiovascular events, including heart attacks, strokes and certain types of heart surgeries, or death compared to patients who remained on Lipitor therapymore...